Archemix Company Information and Contacts

Search

Select Contact

Get Contact

Enter a Title

First Name

Last Name

Title

First Name

Last Name

23 of 23 Contacts found in Archemix ( displayed)

Ga... Mo....
Co-Founder/Director of Business Development

Jigsaw Data Corporation
1700 S Amphlett Blvd Ste 250
San Mateo, CA 94402-2728 USA

Phone XXX.XXX.XXXX
Email XXXXX@XXXXX.XXX

Archemix Company Information on Jigsaw

Headquarter	300 Third Street Cambridge, 02142 www.archemix.com
Country	USA
Phone Number	+1.617.621.7700
Industry	Healthcare, Pharmaceuticals, & Biotech
Employees	100 - 250
Revenue	$1 - 10M
Ownership	Privately Held

23 Archemix Corp. Contacts

See All

Sales	1
Finance & Admin	7
Human Resources	2
Engineering & Research	4
Operations	1
IT & IS	4
Other	4

C-Level	8
VP-Level	5
Director-Level	3
Manager-Level	3
Staff	2
Other	2

Export Archemix data directly into your CRM

Download FREE Company info for Archemix and many more!

Find Companies

Companies by Geography

Public Companies

Companies by Industry

Related Companies

Abbott Laboratories

Bristol-Myers Squibb Company

Glaxo Smith Kline

What is Jigsaw?

Online Directory of over 8 million business contacts—from managers and dirctors to VP and C-level
Company information for millions of companies including data on Archemix
All records include full name, title, postal address, hard-to-find email address and telephone number
Fresh and accurate contact data maintained by over 400,000 members
Search for key decision makers by company, rank, industry, department, geography and more
All the contacts you need at Archemix as well as contacts at Related Companies

archemix.com - Jigsaw Company Wiki Page

Excerpted from the website: Archemix is leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute disease. Archemix is a biopharmaceutical company committed to the discovery and development of aptamer-based therapeutics. Founded in May 2001, we are located in Cambridge, Massachusetts. With an experienced management team, world-class scientists and strong financial backing from leading biotech investors, we are leveraging a dominant patent portfolio and proprietary technologies to create a novel class of therapeutics which encompass many of the benefits of small